Current Cardiovascular Risk Reports

, Volume 7, Issue 5, pp 401–408 | Cite as

Novel Approaches for the Treatment of the Patient with Resistant Hypertension: Renal Nerve Ablation

Secondary Prevention and Intervention (J Foody, Section Editor)

Abstract

Sympathetic innervation of the kidneys plays a major role in the pathogenesis of hypertension through modulation of renin secretion, glomerular filtration rate and renal absorption of sodium. Targeted interventions for renal nerve ablation are being developed for treatment of drug-resistant hypertension in the USA and the rest of the world. Early studies with the use of radiofrequency-based renal denervation systems have shown encouraging results with significant reduction of blood pressure in patients inadequately controlled despite nearly maximal drug therapy regimens. Thus far, the renal denervation procedure has been associated with minimal side effects. Long-term efficacy and safety beyond 3 years needs to be determined for renal nerve ablation. This review focuses on the physiology of the renal sympathetic system, the rationale for renal nerve ablation and current evidence in support of the available therapeutic renal denervation systems.

Keywords

Resistant hypertension Renal denervation Renal nerve ablation Sympathetic nervous system 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Vinay Gulati declares that he has no conflict of interest.

William B. White is a steering committee member for St. Jude Medical.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    World Health Organization. World Health Report 2002: reducing risks, promoting healthy life. Geneva: World Health Organization; 2002.Google Scholar
  2. 2.
    Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43:10–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510–26.PubMedCrossRefGoogle Scholar
  4. 4.
    Egan BM, Zhao Y, Axon RN, et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988–2008. Circulation. 2011;124:1046–58.PubMedCrossRefGoogle Scholar
  5. 5.
    Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension. 2011;57:1076–80.PubMedCrossRefGoogle Scholar
  6. 6.
    Evelyn KA, Alexander F, Cooper SR. Effect of sympathectomy on blood pressure in hypertension: a review of 13 years’ experience of the Massachusetts General Hospital. JAMA. 1949;140:592–602.CrossRefGoogle Scholar
  7. 7.
    Smithwick RH, Bush RD, Kinsey D, Whitelaw GP. Hypertension and associated. cardiovascular disease; comparison of male and female mortality rates and their influence on selection of therapy. JAMA. 1956;160(12):1023–6.CrossRefGoogle Scholar
  8. 8.
    Grimson KS. Total thoracic and partial to total lumbar sympathectomy and celiac ganglionectomy in the treatment of hypertension. Ann Surg. 1941;114:753–75.PubMedGoogle Scholar
  9. 9.
    Smithwick RH. Surgery in hypertension. Lancet. 1948;2:65.PubMedGoogle Scholar
  10. 10.
    Grimson KS, Orgain ES, Anderson B, et al. Results of treatment of patients with hypertension by total thoracic and partial to total lumbar sympathectomy, splanchnicectomy and celiac ganglionectomy. Ann Surg. 1949;129:850–71.CrossRefGoogle Scholar
  11. 11.
    DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77:75–197.PubMedGoogle Scholar
  12. 12.
    Krum H, Sobotka P, Mahfoud F, et al. Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation. 2011;123:209–15.PubMedCrossRefGoogle Scholar
  13. 13.
    Barajas L, Liu L, Powers K. Anatomy of the renal innervation: intrarenal aspects and ganglia of origin. Can J Physiol Pharmacol. 1992;70(5):735–49.PubMedCrossRefGoogle Scholar
  14. 14.
    Esler M, Jennings G, Korner P, et al. The assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension. 1988;11:3–20.PubMedCrossRefGoogle Scholar
  15. 15.
    Esler M. The sympathetic system and hypertension. Am J Hypertens. 2000;13(6 Pt 2):99S–105S.PubMedCrossRefGoogle Scholar
  16. 16.
    Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev. 1991;71:659–82.PubMedGoogle Scholar
  17. 17.
    Ciriello J, de Oliveira CV. Renal afferents and hypertension. Curr Hypertens Rep. 2002;4:136–42.PubMedCrossRefGoogle Scholar
  18. 18.
    Kopp UC, Smith LA, DiBona GF. Renorenal reflexes: neural components of ipsilateral and contralateral renal responses. Am J Physiol. 1985;249:F507–17.PubMedGoogle Scholar
  19. 19.
    Converse Jr RL, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106:1974–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Huysmans FT, van Heusden FH, Wetzels JF, et al. Antihypertensive effect of beta blockade in renal transplant recipients with or without host kidneys. Transplantation. 1988;46:234–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 1999;340:1321–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361(9):932–4.PubMedCrossRefGoogle Scholar
  24. 24.
    Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.PubMedCrossRefGoogle Scholar
  25. 25.
    •• Mahfoud F, Lüscher TF, Andersson B. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J. 2013;34:2149–57. This expert consensus document summarizes the view of an expert panel of the European Society of Cardiology and the European Association of Percutaneous Cardiovascular Interventions to provide guidance regarding renal denervation.PubMedCrossRefGoogle Scholar
  26. 26.
    Prochnau D, Lucas N, Kuehnert H, et al. Catheter-based renal denervation for drug-resistant hypertension by using a standard electrophysiology catheter. EuroIntervention. 2012;7:1077–80.PubMedCrossRefGoogle Scholar
  27. 27.
    The Symplicity HTN-1 Investigators. Three-year follow-up of Symplicity HTN-1 trial. Abstract presented at the 61st Annual Scientific Sessions of the American College of Cardiology. Chicago, IL; 25 March 2012.Google Scholar
  28. 28.
    • Esler MD, Krum H, Sobotka PA, et al. Symplicity HTN-2 investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903–9. The first randomized efficacy study providing evidence of therapeutic benefit of renal sympathetic denervation in patients with resistant hypertension.PubMedCrossRefGoogle Scholar
  29. 29.
    O’Riordan M. BP reductions with renal denervation durable to 30 months: Symplicity HTN-2. theheart.org. [Clinical Conditions > Interventional/Surgery > Interventional/Surgery]. http://www.theheart.org/article/1541263.do. Accessed 28 May 2013.
  30. 30.
    • Kandzari DE, Bhatt DL, Sobotka PA, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the Symplicity HTN-3 trial. Clin Cardiol. 2012;35(9):528–35. The first randomized, placebo-controlled trial to study the long-term efficacy of renal nerve ablation in patients with resistant hypertension.PubMedCrossRefGoogle Scholar
  31. 31.
    Worthley S. Safety and efficacy of a novel quadrapolar renal denervation catheter in patients with resistant hypertension: a first-in-man multicenter study. Abstract presented at the 2012 Annual Scientific Sessions of the European Association for Percutaneous Cardiovascular Interventions. Paris, France; 16 May 2012.Google Scholar
  32. 32.
    Hoppe U. Clinical experience with Vessix Vascular balloon renal denervation catheter. Abstract presented at the 2012 Annual Scientific Sessions of the European Association for Percutaneous Cardiovascular Interventions. Paris, France; 17 May 2012.Google Scholar
  33. 33.
    Ormiston JA, Watson T, van Pelt N, et al. Renal denervation for resistant hypertension using an irrigated radiofrequency balloon: 12-month results from the Renal Hypertension Ablation System (RHAS) trial. EuroIntervention. 2013;9(1):70–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Ahmed H, Neuzil P, Skoda J, et al. Renal sympathetic denervation using an irrigated radiofrequency ablation catheter for the management of drug-resistant hypertension. JACC Cardiovasc Interv. 2012;5:758–65.PubMedCrossRefGoogle Scholar
  35. 35.
    Bonan R. PARADISE: first-in-man results of a novel circumferential catheter-based ultrasound technology for renal denervation. Abstract presented at the 2012 Annual Scientific Sessions of the European Association for Percutaneous Cardiovascular Interventions. Paris, France; 16 May 2012.Google Scholar
  36. 36.
    Manning PT, Powers CW, Schmidt RE, Johnson Jr EM. Guanethidine-induced destruction of peripheral sympathetic neurons occurs by an immune-mediated mechanism. J Neurosci. 1983;3:714–24.PubMedGoogle Scholar
  37. 37.
    Mahfoud F, Cremers B, Janker J, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60:419–24.PubMedCrossRefGoogle Scholar
  38. 38.
    Hering D, Mahfoud F, Walton AS, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23:1250–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Wood S. EnligHTN-1: BP drops durable, safe at one year, as renal-denervation mania grows. theheart.org. [Clinical Conditions > Hypertension > Hypertension]. http://www.theheart.org/article/1543267.do. Accessed 28 May 2013.
  40. 40.
    Ukena C, Mahfoud F, Kindermann I, et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol. 2011;58:1176–82.PubMedCrossRefGoogle Scholar
  41. 41.
    Mahfoud F, Lenski M, Ukena C, et al. Influence of renal sympathetic denervation on orthostatic function in patients with resistant hypertension. Circulation. 2012;126, A17201.Google Scholar
  42. 42.
    Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J. 2012;33:1058–66.PubMedCrossRefGoogle Scholar
  43. 43.
    Petersson M, Friberg P, Eisenhofer G, Lambert G, Rundqvist B. Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J. 2005;26:906–13.PubMedCrossRefGoogle Scholar
  44. 44.
    Davies JE, Manisty CH, Petraco R, et al. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol. 2013;162:189–92.PubMedCrossRefGoogle Scholar
  45. 45.
    Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59:901–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Pokushalov E, Romanov A, Corbucci G, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012;60:1163–70.PubMedCrossRefGoogle Scholar
  47. 47.
    Ukena C, Bauer A, Mahfoud F, et al. Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin Res Cardiol. 2012;101:63–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Grassi G, Dell’Oro R, Quarti-Trevano F, et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia. 2005;48:1359–65.PubMedCrossRefGoogle Scholar
  49. 49.
    Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940–6.PubMedCrossRefGoogle Scholar
  50. 50.
    Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559–65.PubMedCrossRefGoogle Scholar
  51. 51.
    • Geisler BP, Egan BM, Cohen JT, et al. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol. 2012;60:1271–7. The only cost-effectiveness evaluation for renal denervation in resistant hypertension management.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology CenterUniversity of Connecticut Health Center, University of Connecticut School of MedicineFarmingtonUSA

Personalised recommendations